Measuring success in hemophilia gene therapy using a factor level & outcomes yardstick.

about

Measuring success in hemophilia gene therapy using a factor level & outcomes yardstick.

Item

http://www.wikidata.org/entity/Q50195965

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Measuring success in hemophilia gene therapy using a factor level & outcomes yardstick.

@en

Measuring success in hemophilia gene therapy using a factor level & outcomes yardstick.

@nl

type

Item

label

Measuring success in hemophilia gene therapy using a factor level & outcomes yardstick.

@en

Measuring success in hemophilia gene therapy using a factor level & outcomes yardstick.

@nl

prefLabel

Measuring success in hemophilia gene therapy using a factor level & outcomes yardstick.

@en

Measuring success in hemophilia gene therapy using a factor level & outcomes yardstick.

@nl

P1476

Measuring success in hemophilia gene therapy using a factor level & outcomes yardstick.

@en

P2093

Margaret V Ragni

http://www.w3.org/2001/XMLSchema#string

Nicoletta Machin

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

New approaches to gene and cell therapy for hemophilia.

New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.

The Future of Hemophilia Treatment: Longer-Acting Factor Concentrates versus Gene Therapy.

Clinical severity of haemophilia A: does the classification of the 1950s still stand?

Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.

Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies.

Why should we care about quality of life in persons with haemophilia?

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.

P304

83-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1080/17474086.2018.1423961

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29300108

http://www.w3.org/2001/XMLSchema#string